We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Dr. Rubén Hernández Alcoceba, Division of Gene Therapy and Hepatology CIMA -Universidad de Navarra (UNAV)
"Adenoviral vectors"
The Adenoviridae family comprises a wide variety of human and animal viruses sharing genetic and structural characteristics. Their 80-100 nm non-enveloped icosahedral capsids contain core proteins and a ~36 Kb double-stranded genome packed with structural and regulatory genes. The study of adenoviral life cycle and its interactions with the host has revealed fundamental biological processes over several decades, and most likely it will enlighten us for many years to come. More recently, adenoviruses have become versatile platforms for the development of therapeutic agents. The stability of their genome and the relative simplicity of its manipulation have enabled the development of a wide repertoire of adenovirus-based products with different properties, all of them sharing a high transduction efficacy in mammalian cell cultures and in vivo. Their lytic life cycle has been exploited for the development of oncolytic agents, whereas progressive deletions of the viral genomes has resulted in gene therapy vectors with optimal cloning capacity and increased episomal stability. The strong immune responses elicited by adenoviral particles have been a drawback for early generation adenoviral vectors, but they are currently harnessed to develop vaccines and improved cancer immunotherapies.This seminar will cover general characteristics of adenovirus and their adaptation as gene therapy vectors, with special attention to High-Capacity Adenoviral vectors.
Host: Immunomediated Diseases and Innovative Therapies jordi.barquinero@vhir.org
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.